been looking all over for all comer trials…. There just isn’t a lot to be honest. Think that most biotechs and pharma for that matter are risk averse and simply hope a single indication shows efficacy. What does this say about Race’s confidence to run all comers trial, they are going all in!
Keytruda was one of a few all comer approvals and generally a subset biomarker or mutation. Rather than different cancer types. Expecting the readout won’t go unnoticed for long.
Intellectual Property (IP) Waterproofing., page-23
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
